# Characterisation of coronary microvascular dysfunction in patients with severe aortic stenosis undergoing TAVI

Roberto Scarsini[1]*, MD, PhD; Emanuele Gallinoro[2,3], MD, PhD; Marco B. Ancona[4], MD;
Leonardo Portolan[1], MD; Pasquale Paolisso[2,5], MD; Paolo Springhetti[1], MD; Francesco Della Mora[1], MD;
Andrea Mainardi[1], MD; Marta Belmonte[2,5], MD; Francesco Moroni[4], MD; Luca A. Ferri[4], MD;
Barbara Bellini[4], MD; Fillippo Russo[4], MD; Ciro Vella[4], MD; Dario Tino Bertolone[2,5], MD;
Gabriele Pesarini[1], MD, PhD; Giovanni Benfari[1], MD, PhD; Marc Vanderheyden[2], MD;
Matteo Montorfano[4,6], MD; Bernard De Bruyne[2], MD, PhD; Emanuele Barbato[7], MD, PhD; Flavio Ribichini[1], MD

*Corresponding author: Division of Cardiology, Verona University Hospital, Piazzale Aristide Stefani 1, 37126, Verona, Italy.
E-mail: roberto.scarsini@aovr.veneto.it

The authors' affiliations can be found at the end of this article.

R. Scarsini and E. Gallinoro contributed equally.

This paper also includes supplementary data published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-23-00735

**ABSTRACT**

**BACKGROUND:** Microvascular resistance reserve (MRR) is a validated measure of coronary microvascular function independent of epicardial resistances.

**AIMS:** We sought to assess whether MRR is associated with adverse cardiac remodelling, a low-flow phenotype and extravalvular cardiac damage (EVCD) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI).

**METHODS:** Invasive thermodilution-based assessment of the coronary microvascular function of the left anterior descending artery was performed in a prospective, multicentre cohort of patients undergoing TAVI. Coronary microvascular dysfunction (CMD) was defined as the lowest MRR tertile of the study cohort. Haemodynamic measurements were performed at baseline and then repeated immediately after TAVI. EVCD and markers of a low-flow phenotype were assessed with echocardiography.

**RESULTS:** A total of 134 patients were included in this study. Patients with low MRR were more frequently females, had a lower estimated glomerular filtration rate and a higher rate of atrial fibrillation. MRR was significantly lower in patients with advanced EVCD (median 1.80 [1.26-3.30] vs 2.50 [1.87-3.41]; p=0.038) and in low-flow, low-gradient AS (LF LG-AS) (median 1.85 [1.20-3.04] vs 2.50 [1.87-3.40]; p=0.008). Overall, coronary microvascular function tended to improve after TAVI and, in particular, MRR increased significantly after TAVI in the subgroup with low MRR at baseline. However, MRR was significantly impaired in 38 (28.4%) patients immediately after TAVI. Advanced EVCD (adjusted odds ratio 3.08 [1.22-7.76]; p=0.017) and a low-flow phenotype (adjusted odds ratio 3.36 [1.08-10.47]; p=0.036) were significant predictors of CMD.

**CONCLUSIONS:** In this observational, hypothesis-generating study, CMD was associated with extravalvular cardiac damage and a low-flow phenotype in patients with severe AS undergoing TAVI.

Coronary microvascular dysfunction (CMD) in patients with aortic stenosis (AS) and its impact on extravalvular cardiac damage are poorly understood[1]. In the presence of severe AS, coronary physiology is characterised by increased resting coronary flow to match the augmented oxygen demand, leading to exhausted coronary flow reserve (CFR), even in the absence of significant epicardial coronary disease[2]. Microvascular resistance reserve (MRR) is a novel, validated marker of coronary microvascular function[3,4]. MRR is specific for the microcirculation and independent of myocardial mass and driving pressures. Patients with AS showed lower MRR compared with matched controls[2].

Recent research focusing on extravalvular cardiac damage (EVCD) in AS demonstrated that right ventricular dysfunction, pulmonary vasculature impairment and a severe low-flow state reflect advanced cardiac damage and are associated with a worse outcome[5,6].

Abnormally elevated microcirculatory resistances were associated with a low-flow state and markers of adverse remodelling in a small cohort of patients undergoing transcatheter aortic valve implantation (TAVI); however, the association between microvascular dysfunction, EVCD and low-flow state has not yet been clarified[7].

We hypothesised that MRR can be a marker of the complex interplay between an aortic valve obstruction and the cardiac adaptive response. Progressive AS severity leads to increased left ventricular (LV) filling pressures, extravascular compression forces and LV positive remodelling. Ultimately, exhausted compensatory mechanisms may lead to adverse LV remodelling, subendocardial ischaemia, LV fibrosis, vascular remodelling, and CMD. In the course of time, a maladaptive LV response may also cause cardiac damage, including left atrial and right ventricular dysfunction and pulmonary hypertension[5,6,8]. In this study, we sought to assess the clinical features associated with impaired MRR in a prospective, multicentre, international cohort of patients with AS undergoing TAVI. In particular, we aimed to assess if low MRR was associated with a low-flow phenotype and advanced EVCD.

---

Editorial, see page e274

---

## Methods

### STUDY POPULATION

This is a patient-pooled analysis of 3 prospective observational studies conducted in 3 European interventional centres (Verona University Hospital, Italy; Aalst OLV Cardiovascular Center, Belgium; San Raffaele Hospital, Milan, Italy) between January 2021 and May 2023. Details of the studies conducted in Verona University Hospital and Aalst OLV Cardiovascular Center have been previously reported[2,7].

In this analysis, we included severe AS patients undergoing TAVI with thermodilution-derived assessment of the coronary microvascular function in the left anterior descending artery (LAD) during the TAVI procedure, prior to valve implantation. A coronary thermodilution assessment was repeated immediately after TAVI.

The main exclusion criteria were significant angiographic epicardial stenosis in the LAD, previous coronary artery bypass graft surgery, previous anterior myocardial infarction, evidence of chronic total occlusion, haemodynamic instability, and severe chronic kidney disease.

Details of the inclusion and exclusion criteria for each cohort are reported in **Supplementary Appendix 1**. The study flowchart is presented in **Supplementary Figure 1**.

This study was conducted following the Declaration of Helsinki, and it was approved by the institutional review board of each centre involved. Written informed consent was collected from all patients.

### TRANSCATHETER AORTIC VALVE IMPLANTATION

All patients underwent TAVI with transfemoral access under conscious sedation and local anaesthesia. All decisions about the technical aspects of TAVI procedures were left to the operator's discretion. Technical TAVI success was defined according to the Valve Academic Research Consortium (VARC)-3 criteria[9]. Coronary angiography was performed in all the patients to exclude the presence of significant epicardial coronary artery disease, using radial or femoral arterial access with 6 Fr guiding catheters as per standard practice.

### CORONARY MICROCIRCULATORY ASSESSMENT

Intracoronary microcirculatory assessment was performed using a pressure/temperature-sensor wire (PressureWire X Guidewire; Abbott) connected to a dedicated software (CoroFlow; Coroventis). Continuous thermodilution was performed by using a dedicated infusion microcatheter (RayFlow; Hexacath) placed in the proximal part of the artery, as

## Impact on daily practice

Being associated with advanced extravalvular cardiac damage and a low-flow aortic stenosis phenotype, severely impaired microvascular resistance reserve (MRR) can be considered a marker of disease severity in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).

Further investigations are awaited to assess the prognostic impact of coronary microvacular dysfunction in patients with aortic stenosis. Whether patients with moderately impaired coronary microvascular function are associated with early signs of adverse cardiac remodelling and if they can be considered for early treatment remains to be defined.

## Abbreviations

| | | | |
|---|---|---|---|
| **AS** | aortic stenosis | **LF LG-AS** | low-flow low-gradient aortic stenosis |
| **CFR** | coronary flow reserve | **MRR** | microvascular resistance reserve |
| **CMD** | coronary microvascular dysfunction | **NF HG-AS** | normal-flow high-gradient aortic stenosis |
| **EVCD** | extravalvular cardiac damage | **RRR** | resistive reserve ratio |
| **FFR** | fractional flow reserve | **TAVI** | transcatheter aortic valve implantation |

previously described[10,11]. Steady-state hyperaemia was induced by a continuous intracoronary infusion of saline at 20 mL/min or with an intravenous adenosine infusion (140 mcg/kg/min).

Microvascular resistance reserve (MRR) was derived based on intracoronary continuous or bolus thermodilution using a previously validated formula[3]:

$$MRR = \frac{CFR}{FFR} \cdot \frac{Pa \; rest}{Pa \; hyp}$$

Where CFR is coronary flow reserve, FFR is fractional flow reserve and Pa is the aortic pressure invasively measured at rest or during steady state hyperaemia.

Patients were stratified according to tertiles of MRR. Coronary microvascular dysfunction (CMD) was defined as low MRR, defined according to the lowest tertile of MRR.

Coronary microcirculatory assessment is discussed in further detail in **Supplementary Appendix 2**.

### PRE-TAVI ECHOCARDIOGRAPHY
Patients underwent complete two-dimensional (2D) and Doppler echocardiography. Data were saved digitally and subsequently analysed offline using TOMTEC-ARENA TTA2 (TOMTEC Imaging Systems GmbH) by experienced researchers (G. Benfari, P. Paolisso, P. Springhetti) blinded to the medical history of the patients.

Assessment of AS severity and conventional echocardiographic measurements of left and right chambers were performed according to the current recommendations[12-14]. LV global longitudinal strain (LV GLS) and peak atrial longitudinal strain (PALS) were measured using dedicated speckle-tracking software packages (AutoStrain; TOMTEC Imaging Systems GmbH) applying the recommendations provided by recent documents[15-17].

### AORTIC STENOSIS ASSESSMENT AND PHENOTYPING
AS was defined according to the latest international guidelines[12]. Normal-flow high-gradient aortic stenosis (NF HG-AS) was defined as a peak transvalvular velocity >4 m/s, a transvalvular mean gradient >40 mmHg and an aortic valve area <1 cm$^2$ in normal-flow state (left ventricular ejection fraction [LVEF] >50% and stroke volume index [SVi] >35 ml/m$^2$). Low-flow low-gradient AS (LF LG-AS) was defined as an aortic valve area <1cm$^2$ but with a transvalvular mean gradient <40 mmHg and a peak transvalvular velocity <4 m/s in a low-flow state (SVi <35 ml/m$^2$).

### EVALUATION OF EXTRAVALVULAR CARDIAC DAMAGE
The extent of extravalvular cardiac damage (EVCD) was categorised into 5 stages according to a model described by Généreux et al[5], as reported in detail in **Supplementary Appendix 3**.

To evaluate the interaction between measures of coronary microvascular function and EVCD and increase the statistical power, cardiac damage was dichotomised[18] into stages 0-2 (group 1: corresponding to isolated left heart dysfunction) compared with stages 3 and 4 (group 2: damage extending to the pulmonary circulation and right heart involvement) **(Figure 1)**.

### STATISTICAL ANALYSIS
The normal distribution of variables was tested using the Shapiro-Wilk test and histograms. Continuous variables are



**Figure 1.** *Definition of extravalvular cardiac damage. Généreux extravalvular cardiac damage (EVCD) classification was dichotomised into stages 0-2 (isolated left heart dysfunction) and stages 3-4 (advanced extravalvular cardiac damage with right heart involvement). LAVI: left atrial volume index; LV: left ventricular; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; RV: right ventricular; sPAP: systolic pulmonary arterial pressure; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation*

reported as median and interquartile range (IQR) as appropriate. Categorical variables are reported as numbers and percentages.

Continuous variables were compared with the Mann-Whitney U test or Kruskal-Wallis test as appropriate. Frequencies were compared with Fisher's exact test. The Wilcoxon test was used to evaluate variations in coronary physiology indices before and after TAVI. Linear regression models were fitted to evaluate the association between continuous variables. Spearman's correlation coefficients were provided. Logistic regression analysis was performed to identify clinical and echocardiographic determinants of a low MRR and to identify predictors of early post-TAVI MRR improvement – defined as a change from the lowest tertile of pre-TAVI MRR to the intermediate or higher tertile of post-TAVI MRR, or as a change from the intermediate tertile of pre-TAVI MRR to the higher tertile of post-TAVI MRR. Variables with p-value<0.1 at univariable analysis were included in the multivariable regression model. The accuracy of the models was assessed with a receiving operator characteristic (ROC) curve-derived area under the curve (AUC) and compared with the DeLong method. All analyses were performed using SPSS 26 (IBM) and STATA 17 (Stata Corp). A p-value<0.05 was considered statistically significant.

## Results
### STUDY POPULATION AND BASELINE CHARACTERISTICS
A total of 134 patients with severe AS undergoing TAVI were included in this study. The clinical, echocardiographic, procedural, and physiological data of the study population are presented in **Table 1**.

Significant clinical differences were observed across the subgroups, which were defined by tertiles of MRR. In particular, patients in the lowest tertile of MRR were more frequently

**Table 1. Clinical, echocardiographic, procedural and physiological data according to MRR tertiles.**

| | All patients | MRR ≤2 | MRR >2 & ≤3 | MRR >3 | *p*-value overall |
|---|---|---|---|---|---|
| **Clinical data** | | | | | |
| No. of patients | 134 (100) | 45 (33.6) | 44 (32.8) | 45 (33.6) | / |
| Female | 83 (61.9) | 34 (75.6) | 28 (63.6) | 21 (46.7) | 0.017 ¥ |
| Age, years | 83.5 (80.0-86.0) | 85.0 (80.0-87.5) | 83.0 (80.0-85.0) | 83.0 (78.5-86.0) | 0.343 |
| BMI, kg/m² | 24.4 (23.2-27.8) | 24.3 (22.2-27.8) | 24.3 (23.0-27.6) | 24.8 (23.2-28.9) | 0.671 |
| Hypertension | 11 (82.8) | 36 (80.0) | 36 (81.8) | 39 (86.7) | 0.714 |
| Dyslipidaemia | 97 (72.4) | 33 (73.3) | 34 (77.3) | 30 (66.7) | 0.545 |
| Diabetes | 45 (33.6) | 17 (37.8) | 16 (36.4) | 12 (26.7) | 0.506 |
| Smoker (current or former) | 25 (18.7) | 8 (17.8) | 6 (13.6) | 11 (24.4) | 0.434 |
| eGFR CG, ml/min/1.73 m² | 65.0 (47.0-84.1) | 55.0 (40.0-75.5) | 70.5 (51.3-85.0) | 71.9 (54.7-87.0) | 0.031 § ¥ |
| Paroxysmal AF | 18 (13.4) | 8 (17.8) | 4 (9.1) | 6 (13.3) | 0.515 |
| Chronic AF | 18 (13.4) | 10 (22.2) | 0 (0) | 8 (17.8) | 0.001 § † |
| AF (paroxysmal or chronic) | 36 (26.9) | 18 (40.0) | 4 (9.1) | 14 (31.1) | 0.002 § † |
| PVD | 24 (17.9) | 9 (20.0) | 6 (13.6) | 9 (20.0) | 0.693 |
| Previous PCI | 12 (9.0) | 2 (4.4) | 4 (9.1) | 6 (13.3) | 0.337 |
| **Echocardiography** | | | | | |
| Mean gradient, mmHg | 44.0 (36.5-55.0) | 40.0 (31.0-54.0) | 45.0 (40.0-57.0) | 43.5 (40.0-50.0) | 0.251 |
| AVA, cm² | 0.7 (0.5-0.8) | 0.7 (0.5-0.8) | 0.6 (0.5-0.8) | 0.7 (0.5-0.8) | 0.465 |
| LVEF, % | 60 (53-64) | 60 (53.5-64) | 60 (58-65) | 58.5 (51.2-63.8) | 0.480 |
| LVEDV index, ml/m² | 51 (43.2-64.7) | 53 (45.5-66) | 49 (42-64) | 51 (41-68) | 0.552 |
| LV SVi, ml/m² | 38 (33-45) | 34 (29-38) | 40 (35-45) | 41 (33-48) | 0.002 § ¥ |
| LV GLS, −% * | 15 (11-17) | 14.2 (10.5-16.3) | 16.1 (13.0-18.0) | 14.5 (10.0-17.3) | 0.089 § |
| LV mass index, g/m² | 114 (99-129) | 113 (101-128) | 115 (99-131) | 113 (97-127) | 0.836 |
| RWT | 0.51 (0.45-0.60) | 0.53 (0.46-0.61) | 0.50 (0.45-0.58) | 0.51 (0.44-0.60) | 0.548 |
| LV E/e' | 14 (11-19) | 15 (11-19) | 13 (11-18) | 14 (10-18) | 0.747 |
| LAV index, ml/m² | 41 (32-49) | 40 (32-53) | 44 (37-51) | 38 (28-46) | 0.083 † |
| PALS, % ** | 18 (13-26) | 15 (10-21) | 20 (16-26) | 20 (11-28) | 0.026 § ¥ |
| MR more than mild | 41 (30.8) | 13 (28.9) | 15 (34.1) | 13 (29.5) | 0.891 |
| sPAP, mmHg | 35 (30-44) | 40 (31-50) | 31 (25-40) | 32 (28-36) | 0.012 § ¥ |
| TR more than mild | 23 (17.3) | 12 (26.7) | 5 (11.4) | 6 (13.6) | 0.138 |
| TAPSE, mm | 22 (19-24) | 20 (18-24) | 23 (22-26) | 21 (19-24) | 0.003 § † |
| **EVCD and LF LG-AS** | | | | | |
| LF LG-AS | 31 (23.1) | 17 (37.8) | 6 (13.6) | 8 (17.8) | 0.022 § ¥ |
| Généreux stages 3/4 | 31 (23.1) | 17 (37.8) | 5 (11.4) | 9 (20.0) | 0.011 § |
| Généreux stage 4 | 10 (7.5) | 8 (17.8) | 0 (0) | 2 (4.4) | 0.004 § |
| Généreux stage 3 | 21 (15.7) | 9 (20.0) | 5 (11.4) | 7 (15.6) | 0.557 |
| Généreux stage 2 | 86 (64.2) | 23 (51.1) | 33 (75.0) | 30 (66.7) | 0.064 § |
| Généreux stage 1 | 13 (9.7) | 4 (8.9) | 5 (11.4) | 4 (8.9) | 0.875 |
| Généreux stage 0 | 4 (3.0) | 1 (2.2) | 1 (2.3) | 2 (4.4) | 1.000 |
| **Procedural data** | | | | | |
| BE valve | 32 (23.9) | 14 (31.1) | 7 (15.9) | 11 (24.4) | 0.244 |
| **Physiology data** | | | | | |
| MRR pre-TAVI | 2.40 (1.70-3.32) | 1.40 (1.19-1.72) | 2.40 (2.18-2.63) | 3.70 (3.27-4.29) | <0.0001 § ¥ † |
| MRR post-TAVI | 2.66 (1.82-3.42) | 1.88 (1.42-2.76) | 2.57 (2.06-3.70) | 3.24 (2.67-3.92) | <0.0001 § ¥ |
| CFR pre-TAVI | 2.0 (1.43-2.67) | 1.20 (1.00-1.47) | 2.04 (1.72-2.30) | 3.22 (2.58-3.69) | <0.0001 § ¥ † |
| CFR post-TAVI | 2.12 (1.45-2.80) | 1.42 (1.02-2.28) | 2.11 (1.67-3.04) | 2.44 (1.89-3.00) | <0.0001 § ¥ |
| RRR pre-TAVI | 2.23 (1.38-3.36) | 1.20 (1.00-1.64) | 2.23 (1.89-2.68) | 3.7 (3.16-4.95) | <0.0001 § ¥ † |
| RRR post-TAVI | 2.42 (1.70-3.26) | 1.68 (1.11-2.69) | 2.41 (2.13-3.63) | 3.08 (2.45-3.43) | <0.0001 § ¥ |
| FFR pre-TAVI | 0.90 (0.84-0.94) | 0.91 (0.87-0.94) | 0.90 (0.85-0.94) | 0.88 (0.82-0.93) | 0.211 |
| FFR post-TAVI | 0.88 (0.83-0.94) | 0.90 (0.85-0.95) | 0.89 (0.83-0.95) | 0.87 (0.82-0.91) | 0.340 |

Data are presented as number (%) or median (interquartile range). § p-value significant for comparison of 1 vs 2; ¥ p-value significant for comparison of 1 vs 3; † p-value significant for comparison of 2 vs 3; * missing values for 46 patients (43.3%); ** missing values for 49 patients (36.6%). AF: atrial fibrillation; AVA: aortic valve area; BE: balloon-expandable; BMI: body mass index; CFR: coronary flow reserve; eGFR CG: estimated glomerular filtration rate (Cockcroft-Gault method); EVCD: extravalvular cardiac damage; FFR: fractional flow reserve; GLS: global longitudinal strain; LAV: left atrial volume; LF LG-AS: low-flow low-gradient aortic stenosis; LV: left ventricular; LVEDV: LV end-diastolic volume; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; MRR: microvascular resistance reserve; No.: number; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease; RRR: resistive reserve ratio; RWT: relative wall thickness; sPAP: systolic pulmonary arterial pressure; SVi: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; TAVI: transcatheter aortic valve implantation; TR: tricuspid regurgitation

females (34 [75.6%] vs 28 [63.6%] and 21 [46.7%]; p=0.017) with lower estimated glomerular filtration rate (eGFR; median 55.0 [IQR 40.0-75.5] vs 70.5 [51.3-85.0] and 71.9 [54.7-87.0] ml/min/1.73 m²; p=0.031) and a higher rate of chronic atrial fibrillation (10 [22.2%] vs 0 [0%] and 8 [17.8%]; p=0.001) compared with the patients in the second tertile and highest tertile, respectively.

The median MRR was 1.40 (1.19-1.72) in the lowest tertile, 2.40 (2.18-2.63) in the second tertile, and 3.70 (3.27-4.29) in the highest tertile. Furthermore, patients with low MRR showed lower values of CFR (median 1.20 [1.00-1.47] vs 2.04 [1.72-2.30] and 3.22 [2.58-3.69]; p<0.0001) and resistive reserve ratio (RRR; median 1.20 [1.00-1.64] vs 2.23 [1.89-2.68] and 3.70 [3.16-4.95]; p<0.0001) compared with

**Table 2. Clinical, echocardiographic, procedural and physiological data according to the degree of EVCD.**

| | All patients | Généreux stages 0-2 | Généreux stages 3-4 | *p*-value |
|---|---|---|---|---|
| **Clinical data** | | | | |
| No. of patients | 134 (100) | 103 (76.9) | 31 (23.1) | / |
| Female | 83 (61.9) | 61 (59.2) | 22 (71.0) | 0.294 |
| Age, years | 83.5 (80.0-86.0) | 82.0 (79.0-86.0) | 86.0 (82.0-88.0) | 0.002 |
| BMI, kg/m² | 24.4 (23.2-27.8) | 24.4 (22.8-27.8) | 24.8 (23.5-26.7) | 0.492 |
| Hypertension | 11 (82.8) | 83 (80.6) | 28 (90.3) | 0.281 |
| Dyslipidaemia | 97 /72.4 | 74 (71.8) | 23 (74.2) | 1.000 |
| Diabetes | 45 (33.6) | 37 (35.9) | 8 (25.8) | 0.387 |
| Smoker (current or former) | 25 (18.7) | 20 (19.4) | 5 (16.1) | 0.797 |
| eGFR CG, ml/min/1.73 m² | 65.0 (47.0-84.1) | 65.0 (48.0-85.0) | 64.0 (43.0-84.0) | 0.673 |
| Paroxysmal atrial fibrillation | 18 (13.4) | 13 (12.6) | 5 (16.1) | 0.564 |
| Chronic atrial fibrillation | 18 (13.4) | 9 (8.7) | 9 (29.0) | 0.007 |
| AF (chronic or paroxysmal) | 36 (26.9) | 22 (21.4) | 14 (45.2) | 0.012 |
| Peripheral vascular disease | 24 (17.9) | 22 (21.4) | 2 (6.5) | 0.065 |
| Previous PCI | 12 (9.0) | 7 (6.8) | 5 (16.1) | 0.148 |
| **Echocardiographic data pre-TAVI** | | | | |
| Mean gradient, mmHg | 44.0 (36.5-55.0) | 45.0 (39.5-56.2) | 40.0 (32.0-47.0) | 0.058 |
| AVA, cm² | 0.7 (0.5-0.8) | 0.7 (0.5-0.8) | 0.7 (0.5-0.9) | 0.844 |
| LVEF, % | 60 (53-64) | 60 (55-65) | 58 (52-60) | 0.019 |
| LVEDV index, ml/m² | 51.0 (43.2-64.7) | 53.0 (43.0-66.5) | 49.0 (45.0-60.0) | 0.725 |
| LV SVi, ml/m² | 38 (33-45) | 39 (34-46) | 35 (30-42) | 0.010 |
| LV GLS, −% * | 15 (11-17) | 15 (12-18) | 14 (10-16) | 0.155 |
| LV mass index, g/m² | 114 (99-129) | 114 (99-129) | 115 (99-131) | 0.846 |
| RWT | 0.51 (0.45-0.60) | 0.51 (0.45-0.61) | 0.50 (0.43-0.57) | 0.186 |
| LV E/e' ** | 14 (11-19) | 14 (11-18) | 14 (11-21) | 0.594 |
| LAV index, ml/m² | 41 (32-49) | 40 (32-48) | 45 (36-53) | 0.157 |
| PALS, % *** | 18 (13-26) | 21(14-27) | 15 (10-20) | 0.024 |
| MR more than mild | 41 (30.8) | 24 (23.5) | 17 (54.8) | 0.002 |
| sPAP, mmHg **** | 35 (30-44) | 31 (25-38) | 45 (35-55) | <0.0001 |
| TR more than mild | 23 (17.3) | 0 (0) | 23 (74.2) | <0.0001 |
| TAPSE, mm | 22 (19-24) | 22 (20-24) | 19 (16-25) | 0.050 |
| **LF LG-AS** | | | | |
| LF LG-AS | 31 (23.1) | 21 (20.4) | 10 (32.3) | 0.224 |
| **Procedural data** | | | | |
| Balloon-expandable valve | 32 (23.9) | 25 (24.3) | 7 (22.6) | 1.000 |
| **Physiology data** | | | | |
| MRR pre-TAVI | 2.40 (1.70-3.32) | 2.50 (1.87-3.41) | 1.80 (1.26-3.30) | 0.038 |
| MRR post-TAVI | 2.66 (1.82-3.42) | 2.65 (1.82-3.44) | 2.69 (1.82-3.40) | 0.750 |
| CFR pre-TAVI | 2.00 (1.43-2.67) | 2.07 (1.46-2.68) | 1.79 (1.20-2.55) | 0.193 |
| CFR post-TAVI | 2.12 (1.45-2.80) | 2.09 (1.42-2.80) | 2.24 (1.52-2.71) | 0.625 |
| RRR pre-TAVI | 2.23 (1.38-3.36) | 2.47 (1.68-3.45) | 1.64 (1.13-2.96) | 0.015 |
| RRR post-TAVI | 2.42 (1.70-3.26) | 2.48 (1.70-3.28) | 2.36 (1.74-3.22) | 0.767 |
| FFR pre-TAVI | 0.90 (0.84-0.94) | 0.90 (0.84-0.94) | 0.89 (0.82-0.94) | 0.318 |
| FFR post-TAVI | 0.88 (0.83-0.94) | 0.88 (0.84-0.94) | 0.87 (0.80-0.92) | 0.196 |

Data are presented as number (%) or median (interquartile range). * missing values for 46 patients (43.3%); ** missing values for 20 patients (14.9%); *** missing values for 49 patients (36.6%); **** missing values for 20 patients (14.9%). AF: atrial fibrillation; AVA: aortic valve area; BMI: body mass index; CFR: coronary flow reserve; eGFR CG: estimated glomerular filtration rate (Cockcroft-Gault method); EVCD: extravalvular cardiac damage; FFR: fractional flow reserve; GLS: global longitudinal strain; LAV: left atrial volume; LF LG-AS: low-flow low-gradient aortic stenosis; LV: left ventricular; LVEDV: LV end-diastolic volume; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; MRR: microvascular resistance reserve; No.: number; PALS: peak atrial longitudinal strain; PCI: percutaneous coronary intervention; RRR: resistive reserve ratio; RWT: relative wall thickness; sPAP: systolic pulmonary arterial pressure; SVi: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; TAVI: transcatheter aortic valve implantation; TR: tricuspid regurgitation

the rest of the study cohort. Conversely, FFR was not significantly different in the 3 subgroups (median 0.91 [0.87-0.94] vs 0.90 [0.85-0.94] and 0.88 [0.82-0.93]; p=0.211).

### MRR AND ADVANCED EXTRAVALVULAR CARDIAC DAMAGE

Overall, 31 patients (23.1%) were characterised by advanced EVCD (Généreux stages 3-4). The clinical, echocardiographic, procedural, and physiological data of patients according to ECVD are presented in **Table 2**. MRR was significantly lower in patients with advanced EVCD (median 1.80 [1.26-3.30]

vs 2.50 [1.87-3.41]; p=0.038) compared with patients in Généreux stages 0-2. Similarly, RRR was significantly reduced in patients with advanced EVCD (median 1.64 [1.13-2.96] vs 2.47 [1.68-3.45]; p=0.015). Conversely, CFR (median 1.79 [1.20-2.55] vs 2.07 [1.46-2.68]; p=0.193) and FFR (median 0.89 [0.82-0.94] vs 0.90 [0.84-0.94]; p=0.318) were not significantly different in the two subgroups **(Central illustration)**. Patients in the lowest tertile of MRR were more frequently categorised as Généreux stages 3-4 compared with patients in the second and third tertiles of MRR

**Coronary physiology data stratified according to extravalvular cardiac damage.**

*Coronary microvascular function expressed by MRR (A) and RRR (C) was significantly impaired in patients with advanced extravalvular cardiac damage. CFR and FFR were not significantly different between patients with and without advanced extravalvular cardiac damage (B and D). CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation*

**Table 3. Clinical, echocardiographic, procedural and physiological data according to AS phenotype.**

| | Overall | NF HG-AS | LF LG-AS | *p*-value |
|---|---|---|---|---|
| **Clinical data** | | | | |
| No. of patients | 134 (100) | 103 (76.9) | 31 (23.1) | |
| Female | 83 (61.9) | 70 (68.0) | 13 (41.9) | 0.012 |
| Age, years | 83.5 (80.0-86.0) | 84.0 (80.0-86.0) | 82.0 (80.0-87.0) | 0.953 |
| BMI, kg/m² | 24.4 (23.2-27.8) | 24.3 (23-27.8) | 24.8 (23.3-29.4) | 0.754 |
| Hypertension | 11 (82.8) | 85 (82.5) | 26 (83.9) | 1.000 |
| Dyslipidaemia | 97 (72.4) | 78 (75.7) | 19 (61.3) | 0.168 |
| Diabetes | 45 (33.6) | 32 (31.1) | 13 (41.9) | 0.283 |
| Smoker (current or former) | 25 (18.7) | 22 (21.4) | 3 (9.7) | 0.191 |
| eGFR CG, ml/min/1.73 m² | 65.0 (47.0-84.1) | 69.0 (53.0-85.0) | 53.0 (43.0-72.0) | 0.047 |
| Paroxysmal AF | 18 (13.4) | 12 (11.7) | 6 (19.4) | 0.366 |
| Chronic AF | 18 (13.4) | 8 (7.8) | 10 (32.3) | 0.001 |
| AF (chronic or paroxysmal) | 36 (26.9) | 20 (19.4) | 16 (51.6) | 0.001 |
| Peripheral vascular disease | 24 (17.9) | 13 (12.6) | 11 (35.5) | 0.007 |
| Previous PCI | 12 (9.0) | 11 (10.7) | 1 (3.2) | 0.294 |
| **Echocardiographic data pre-TAVI** | | | | |
| Mean gradient, mmHg | 44.0 (36.5-55.0) | 47.0 (41.0-58.0) | 30.0 (20.7-34.5) | <0.0001 |
| AVA, cm² | 0.7 (0.5-0.8) | 0.7 (0.5-0.8) | 0.8 (0.6-0.9) | 0.001 |
| LVEF, % | 60 (53-64) | 60 (57-65) | 49 (33-64) | <0.0001 |
| LVEDV index, ml/m² | 51.0 (43.2-64.7) | 50.0 (43.0-60.0) | 67.0 (46.0-92.0) | 0.001 |
| LV SVi, ml/m² | 38 (33-45) | 40 (35-47) | 30 (28-34) | <0.0001 |
| LV GLS, −% * | 15 (11-17) | 16 (14-18) | 9 (7-12) | <0.0001 |
| LV mass index, g/m² | 114 (99-129) | 113 (99-128) | 118 (100-144) | 0.394 |
| RWT | 0.51 (0.45-0.60) | 0.51 (0.45-0.58) | 0.50 (0.45-0.67) | 0.425 |
| LV E/e' | 14 (11-19) | 14 (11-19) | 12 (8-18) | 0.181 |
| LAV index, ml/m² | 41 (32-49) | 39 (32-47) | 45 (39-57) | 0.008 |
| PALS, % ** | 18 (13-26) | 21 (15-27) | 11 (6-15) | <0.0001 |
| MR more than mild | 41 (30.8) | 32 (31.1) | 9 (30) | 1.000 |
| sPAP, mmHg | 35 (30-44) | 35 (30-44) | 36 (28-44) | 0.561 |
| TR more than mild | 23 (17.3) | 16 (15.5) | 7 (23.3) | 0.410 |
| TAPSE, mm | 22 (19-24) | 22 (20-25) | 19 (16-24) | 0.001 |
| **EVCD** | | | | |
| Généreux stages 3/4 | 31 (23.1) | 21 (20.4) | 10 (32.3) | 0.224 |
| Généreux stage 4 | 10 (7.5) | 3 (2.9) | 7 (22.6) | 0.001 |
| Généreux stage 3 | 21 (15.7) | 18 (17.5) | 3 (9.7) | 0.403 |
| Généreux stage 2 | 86 (64.2) | 66 (64.1) | 20 (64.5) | 1.000 |
| Généreux stage 1 | 13 (9.7) | 12 (11.7) | 1 (3.2) | 0.298 |
| Généreux stage 0 | 4 (3.0) | 4 (3.9) | 0 (0) | 0.573 |
| **Procedural data** | | | | |
| Balloon-expandable valve | 32 (23.9) | 17 (16.5) | 15 (48.4) | 0.001 |
| **Physiology data** | | | | |
| MRR pre-TAVI | 2.40 (1.70-3.32) | 2.50 (1.87-3.40) | 1.85 (1.20-3.05) | 0.008 |
| MRR post-TAVI | 2.66 (1.82-3.42) | 2.75 (2.04-3.64) | 2.25 (1.51-3.28) | 0.057 |
| CFR pre-TAVI | 2.0 (1.43-2.67) | 2.10 (1.50-2.68) | 1.69 (1.06-2.30) | 0.029 |
| CFR post-TAVI | 2.12 (1.45-2.80) | 2.16 (1.59-2.80) | 1.79 (1.31-2.84) | 0.344 |
| RRR pre-TAVI | 2.23 (1.38-3.36) | 2.45 (1.64-3.42) | 1.80 (1.17-2.86) | 0.024 |
| RRR post-TAVI | 2.42 (1.70-3.26) | 2.53 (1.83-3.25) | 2.18 (1.42-3.28) | 0.191 |
| FFR pre-TAVI | 0.90 (0.84-0.94) | 0.89 (0.83-0.93) | 0.93 (0.89-0.96) | 0.006 |
| FFR post-TAVI | 0.88 (0.83-0.94) | 0.87 (0.81-0.91) | 0.95 (0.89-0.96) | <0.0001 |

Data are presented as number (%) or median (interquartile range). *missing values for 46 patients (43.3%); **missing values for 49 patients (36.6%).
AF: atrial fibrillation; AS: aortic stenosis; AVA: aortic valve area; BMI: body mass index; CFR: coronary flow reserve; eGFR CG: estimated glomerular filtration rate (Cockcroft-Gault method); EVCD: extravalvular cardiac damage; FFR: fractional flow reserve; GLS: global longitudinal strain; LAV: left atrial volume; LF LG-AS: low-flow low-gradient aortic stenosis; LV: left ventricular; LVEDV: LV end-diastolic volume; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; MRR: microvascular resistance reserve; NF HG-AS: normal-flow high-gradient aortic stenosis; No.: number; PALS: peak atrial longitudinal strain; PCI: percutaneous coronary intervention; RRR: resistive reserve ratio; RWT: relative wall thickness; sPAP: systolic pulmonary arterial pressure; SVi: stroke volume index; TAPSE: tricuspid annular plane systolic excursion; TAVI: transcatheter aortic valve implantation; TR: tricuspid regurgitation

(17 [37.8%] vs 5 [11.4%] vs 9 [20.0%]; p=0.011) **(Table 1)**. The overall Généreux classification of EVCD is presented in **Supplementary Figure 2**. Patients in stage 4 showed lower values of MRR (p=0.033) and RRR (p=0.048) compared with the other subgroups **(Supplementary Figure 2)**. **Supplementary Table 1** shows the incidence of advanced EVCD (Généreux stages 3-4) in patients stratified according to different, previously described, cutoffs of MRR[4,19].

### MRR AND A LOW-FLOW LOW-GRADIENT PHENOTYPE

Thirty-one patients (23.1%) were classified as LF LG-AS. The clinical, echocardiographic, procedural, and physiological data of patients stratified according to the AS phenotype are presented in **Table 3**. MRR (median 1.85 [1.20-3.04] vs 2.50 [1.87-3.40]; p=0.008), RRR (median 1.80 [1.17-2.86] vs 2.45 [1.64-3.42]; p=0.024) and CFR (median 1.69 [1.06-2.30] vs 2.10 [1.50-2.68];

p=0.029) were significantly lower and FFR was significantly higher (median 0.93 [0.89-0.96] vs 0.89 [0.83-0.93]; p=0.006) in patients with LF LG-AS compared with patients with normal-flow high-gradient AS **(Figure 2)**.

Patients with low MRR were more frequently classified as LF LG-AS (17 [37.8%] vs 6 [13.6%] vs 8 [17.8%]; p=0.022), and they showed lower values of SVi (median 34 [29-38] vs 40 [35-45] vs 41 (33-48) ml/m²; p=0.002) **(Table 1)**.

### MRR, THE LEFT ATRIUM AND THE LEFT VENTRICLE

Patients with low MRR showed a trend toward larger left atria (median 40 [32-53] vs 44 [37-51] vs 38 [28-46] ml/m²; p=0.083). No differences were observed across patients stratified by MRR tertiles in terms of LV mass index (median 113 [101-128] vs 115 [99-131] vs 113 [97-127] g/m²; p=0.836), relative wall thickness (RWT; median 0.53 [0.46-0.61] vs 0.50 [0.45-0.58] vs 0.51



**Figure 2.** *Coronary physiology data in patients with LF LG-AS versus NF HG-AS. Coronary microvascular function expressed by MRR (A), CFR (B) and RRR (C) was significantly impaired in patients with LF LG-AS compared with those with NF HG-AS. FFR was significantly lower in patients with NF HG-AS (D). CFR: coronary flow reserve; FFR: fractional flow reserve; LF LG-AS: low-flow low-gradient aortic stenosis; MRR: microvascular resistance reserve; NF HG-AS: normal-flow high-gradient aortic stenosis; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation*

[0.44-0.60]; p=0.548), LV end-diastolic volume index (median 53.0 [45.5-66.0] vs 49.0 [42.0-64.0] vs 51.0 [41.0-68.0] ml/m²; p=0.552) or LVEF (median 60.0 [53.5-64.0] vs 60.0 [58.0-65.0] vs 58.5 [51.2-63.8]; p=0.480) **(Table 1)**.

The median LV GLS was numerically lower (14.2 [10.5-16.3] vs 16.1 [13.0-18.0] vs 14.5 [10.0-17.3]; p=0.089) and left atrial function expressed by PALS was significantly reduced (15 [10-21] vs 20 [16-26] vs 20 [11-28]; p=0.026) in patients with low MRR. MRR was linearly correlated with PALS (Rho 0.267; p=0.013) and SVi (Rho 0.242; p=0.006) **(Supplementary Figure 3)**.

## PREDICTORS OF LOW MRR

Predictors of low MRR at univariable logistic regression analysis are shown in **Supplementary Table 2**. The multivariable model including female gender, eGFR (Cockroft-Gault [CG] method) <60 ml/min, advanced EVCD (Généreux stages 3-4) and a low-flow phenotype (SVi <30 ml/min) demonstrated an overall good performance in predicting low MRR (AUC 0.78 [0.68-0.86]; p<0.001) **(Figure 3)**.

## ACUTE VARIATIONS OF CORONARY MICROCIRCULATORY FUNCTION IMMEDIATELY AFTER TAVI

The TAVI procedure was successful in 134 (100%) patients. Overall, MRR tended to improve (2.40 [1.70-3.32] vs 2.66 [1.82-3.42]; p=0.094) and FFR decreased significantly after TAVI (0.90 [0.84-0.94] vs 0.88 [0.83-0.94]; p=0.014). MRR was severely reduced (≤2.0) after TAVI in 38 (28.4%) patients. Conversely, neither CFR (2.0 [1.43-2.67] vs 2.12 [1.45-2.80]; p=0.805) nor RRR (2.23 [1.38-3.36] vs 2.42 [1.70-3.26]; p=0.671) showed significant variations after TAVI **(Supplementary Figure 4)**.

Considering only patients in the lowest tertile of MRR at baseline, we observed a significant improvement of coronary microvascular function after TAVI expressed by MRR (1.40 [1.19-1.72] vs 1.88 [1.42-2.76]; p<0.0001), RRR (1.2 [1.00-1.64] vs 1.68 [1.11-2.69]; p<0.0001) and CFR (1.2 [1.0-1.47] vs 1.42 [1.02-2.28]; p=0.005) **(Supplementary Figure 5)**.

Similarly, in patients with advanced EVCD, MRR improved significantly after TAVI (1.80 [1.26-3.30] vs 2.69 [1.82-3.40]; p=0.014) and RRR showed a trend towards improvement (1.64 [1.13-2.96] vs 2.36 [1.74-3.22]; p=0.091). Conversely, CFR (1.79 [1.20-2.55] vs 2.24 [1.52-2.71], p=0.210) did not change significantly after TAVI **(Supplementary Figure 6)**.

Predictors of early MRR improvement after TAVI are reported in **Supplementary Table 3**.

## Discussion

We demonstrated that invasively assessed CMD is associated with unfavourable features at non-invasive imaging in a multi-centre, international, prospective cohort of patients undergoing TAVI **(Central illustration)**. MRR, a novel and recently validated index of microvascular function, is associated with a low-flow phenotype in patients with severe AS. In particular, patients with low MRR exhibited significantly lower SVi compared with the rest of the study cohort. Moreover, CMD is associated with advanced EVCD. In particular, patients with severely impaired MRR tend to show impaired left atrial function, right ventricular dysfunction and pulmonary hypertension. In most of the patients, coronary microvascular



| Best model in predicting the lower tertile of MRR | | | |
|---|---|---|---|
| **Variables** | **aOR (95% CI)** | **p-value** | **AUC (95% CI)** |
| Female gender | **3.651 (1.365-9.766)** | 0.010 | |
| eGFR CG <60 ml/min | **4.455 (1.857-10.686)** | 0.001 | **0.78 (0.68-0.86)** |
| Advanced EVCD (Généreux stages 3-4) | **3.077 (1.220-7.761)** | 0.017 | |
| Low-flow phenotype (SVi <30 ml/m²) | **3.365 (1.082-10.468)** | 0.036 | |

**Figure 3.** *Predictors of low pre-TAVI microvascular resistance reserve. The multivariable logistic regression model including female gender, eGFR CG <60 ml/min, advanced EVCD (Généreux stages 3-4) and low-flow phenotype (SVi <30 ml/min) demonstrated good accuracy in predicting a low MRR. aOR: adjusted odds ratio; AUC: area under curve; CI: confidence interval; eGFR CG: estimated glomerular filtration rate (Cockroft-Gault method); EVCD: extravalvular cardiac damage; MRR: microvascular resistance reserve; ROC: receiver operating characteristic; SVi: stroke volume index; TAVI: transcatheter aortic valve implantation*

function tended to improve. This is likely due to the effect of LV unloading induced by TAVI.

Coronary microvascular function improved significantly after TAVI in the subgroup of patients in the lowest tertile of MRR. However, in a subgroup of patients, MRR remained severely impaired immediately after TAVI. This may be related to the development of structural coronary microvascular dysfunction caused by chronic vascular remodelling with abnormally upraised fixed microcirculatory resistance. Nevertheless, it must be acknowledged that data on long-term variations of MRR after TAVI were not available in this study. Therefore, it is possible that with the regression of LV hypertrophy, microvascular function and, subsequently, MRR may improve over time. Indeed, Rajappan et al demonstrated that CFR does not improve immediately after surgical aortic valve replacement. However, significant variations of CFR were observed up to 12 months after surgery[20]. Other investigators observed that hyperaemic coronary flow increases significantly, whereas no significant variations in resting coronary flow were observed immediately after TAVI[21]. Whether MRR may further improve in the long term after TAVI remains to be defined.

## MRR, EXTRAVALVULAR CARDIAC DAMAGE AND A LOW-FLOW PHENOTYPE

The left ventricular response to AS is initially adaptive, but it becomes soon maladaptive with excessive LV hypertrophy and

concentric remodelling[8,22]. Increased LV filling pressures translate into left atrial dysfunction and high pulmonary pressures and, ultimately, into right ventricular dysfunction and low cardiac output[8,22]. EVCD is associated with adverse long-term clinical outcomes in AS patients treated with TAVI[5,6]. In this study, low MRR was associated with right ventricular dysfunction, high pulmonary pressures and a low stroke volume index. Therefore, impaired MRR could emerge as a possible marker of EVCD and a low-flow AS phenotype.

CMD was previously associated with myocardial fibrosis in patients with LF LG-AS, and fibrosis is likely to contribute to LV adverse remodelling exacerbating subendocardial ischaemia[1,23,24].

We previously demonstrated that coronary microcirculatory resistances are abnormally elevated in specific subgroups of patients with AS. In fact, LF LG-AS were associated with a high index of microcirculatory resistance and low CFR in a previous prospective investigation[7]. In this study we confirmed and further expanded our observations in a larger and multicentric cohort assessed with thermodilution-based invasive coronary physiology. Notably, MRR, CFR and RRR were significantly lower in patients with LF LG-AS, confirming the severity of coronary microcirculatory function impairment in this subset. Whether CMD plays a key role in the pathophysiology of patients with LF LG-AS or can be seen as a marker of end-stage low-flow state remains to be determined.

### CLINICAL IMPLICATIONS OF CORONARY MICROVASCULAR ASSESSMENT IN TAVI CANDIDATES
This study provided insights on the complex interplay between coronary microvascular function, LV remodelling and EVCD in patients with AS. Notably, the MRR threshold used in this study to define CMD was very similar to the best cutoff observed by other investigators in a different clinical setting[19]. Patients with CMD (MRR ≤2.0) showed unfavourable echocardiographic features with signs of advanced and potentially irreversible cardiac damage. On one hand, subclinical abnormalities in coronary microvascular function might reveal initial signs of adverse cardiac remodelling. On the other hand, overt impairment of coronary microvascular function, detected at the end stage in the natural history of AS and depicted in this study as low MRR, may act as a marker of disease severity and poor prognosis. This hypothesis requires future additional dedicated investigations.

### Limitations
The results of this study must be analysed in light of some limitations, and they should be considered hypothesis-generating, requiring further investigation to confirm our initial observations. First, the sample size was relatively small. However, to the best of our knowledge, this is the largest reported cohort of patients with severe AS who underwent invasive thermodilution-derived assessment of coronary microcirculation. Second, some variability in the eligibility criteria and in the modality of the microvascular assessment in the 3 subcohorts of this study may have introduced biases. In particular, differences in the exclusion criteria at the 3 enrolling centres, as reported in the supplementary material, must be acknowledged. Moreover, coronary microvascular assessment was performed using continuous intracoronary infusion of saline for absolute flow derivation in a subgroup of patients and using bolus thermodilution in the rest of the study population. Indeed, unlike bolus thermodilution assessment, absolute flow assessment based on continuous intracoronary infusion of saline is considered operator-independent. Moreover, saline infusion at 20 ml/min induces particularly stable hyperaemic conditions without significant haemodynamic influence. However, the formula used for MRR derivation in this study allows the possible impact of pharmacologically induced hyperaemia on coronary haemodynamics to be taken into account in patients who underwent microvascular assessment based on bolus thermodilution, as described in the MRR original validation study[3].

Third, long-term data on coronary microvascular assessment and non-invasive cardiac imaging after TAVI were not available. Fourth, this study was not designed to assess differences in prognosis, and long-term clinical outcomes were not available. Larger prospective studies with long-term follow-up are warranted to define the prognostic role of CMD in patients undergoing TAVI and to identify the best cutoff value of MRR for risk stratification in this specific clinical setting.

### Conclusions
In this observational, hypothesis-generating study, coronary microvascular dysfunction, defined by thermodilution-derived MRR, was associated with extravalvular cardiac damage and a low-flow phenotype in patients with severe AS undergoing TAVI. Further investigations are needed to assess whether MRR is a valuable prognostic marker in patients undergoing TAVI.

### Authors' affiliations
*1. Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy; 2. Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; 3. Division of University Cardiology, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy; 4. Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 5. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; 6. School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; 7. Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy*

### Conflict of interest statement
R. Scarsini reports research grant from Abbott and Philips; and speaker fees from Abbott. F. Ribichini reports research grant from Abbott and Philips. P. Paolisso, M. Belmonte, and D.T. Bertolone are supported by a research grant from the CardioPaTh PhD Program. E. Barbato declares speaker fees from Abbott, Boston Scientific, and GE HealthCare. B. De Bruyne has received consultancy fees from Boston Scientific and Abbott; research grants from Coroventis Research, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow, and Abbott; and owns equity in Siemens, GE HealthCare, Philips, HeartFlow, Edwards Lifesciences, Bayer, Sanofi, and Celiad. M.B. Ancona received consultant fees from Abbott and Abiomed. M. Montorfano is a proctor for

Abbott, Kardia, and Boston Scientific. The other authors have no conflicts of interest to declare.

# References

1. McConkey HZR, Marber M, Chiribiri A, Pibarot P, Redwood SR, Prendergast BD. Coronary Microcirculation in Aortic Stenosis. *Circ Cardiovasc Interv.* 2019;12:e007547.

2. Paolisso P, Gallinoro E, Vanderheyden M, Esposito G, Bertolone DT, Belmonte M, Mileva N, Bermpeis K, De Colle C, Fabbricatore D, Candreva A, Munhoz D, Degrieck I, Casselman F, Penicka M, Collet C, Sonck J, Mangiacapra F, de Bruyne B, Barbato E. Absolute coronary flow and microvascular resistance reserve in patients with severe aortic stenosis. *Heart.* 2022;109:47-54.

3. De Bruyne B, Pijls NHJ, Gallinoro E, Candreva A, Fournier S, Keulards DCJ, Sonck J, Van't Veer M, Barbato E, Bartunek J, Vanderheyden M, Wyffels E, De Vos A, El Farissi M, Tonino PAL, Muller O, Collet C, Fearon WF. Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function: JACC Technology Corner. *J Am Coll Cardiol.* 2021;78:1541-9.

4. Boerhout CKM, Lee JM, de Waard GA, Mejia-Renteria H, Lee SH, Jung JH, Hoshino M, Echavarria-Pinto M, Meuwissen M, Matsuo H, Madera-Cambero M, Eftekhari A, Effat MA, Murai T, Marques K, Doh JH, Christiansen EH, Banerjee R, Nam CW, Niccoli G, Nakayama M, Tanaka N, Shin ES, Appelman Y, Beijk MAM, van Royen N, Knaapen P, Escaned J, Kakuta T, Koo BK, Piek JJ, van de Hoef TP. Microvascular resistance reserve: diagnostic and prognostic performance in the ILIAS registry. *Eur Heart J.* 2023;44:2862-9.

5. Généreux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, Svensson LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, Kodali SK, Smith CR, Miller DC, Webb JG, Leon MB. Staging classification of aortic stenosis based on the extent of cardiac damage. *Eur Heart J.* 2017;38:3351-8.

6. Tastet L, Tribouilloy C, Maréchaux S, Vollema EM, Delgado V, Salaun E, Shen M, Capoulade R, Clavel MA, Arsenault M, Bédard É, Bernier M, Beaudoin J, Narula J, Lancellotti P, Bax JJ, Généreux P, Pibarot P. Staging Cardiac Damage in Patients With Asymptomatic Aortic Valve Stenosis. *J Am Coll Cardiol.* 2019;74:550-63.

7. Scarsini R, Pighi M, Mainardi A, Portolan L, Springhetti P, Mammone C, Della Mora F, Fanti D, Tavella D, Gottin L, Bergamini C, Benfari G, Pesarini G, Ribichini FL. Proof of concept study on coronary microvascular function in low flow low gradient aortic stenosis. *Heart.* 2023;109:785-93.

8. Treibel TA, Badiani S, Lloyd G, Moon JC. Multimodality Imaging Markers of Adverse Myocardial Remodeling in Aortic Stenosis. *JACC Cardiovasc Imaging.* 2019;12:1532-48.

9. VARC-3 WRITING COMMITTEE: Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. *J Am Coll Cardiol.* 2021;77:2717-46.

10. Candreva A, Gallinoro E, Fernandez Peregrina E, Sonck J, Keulards DCJ, Van't Veer M, Mizukami T, Pijls NHJ, Collet C, De Bruyne B. Automation of intracoronary continuous thermodilution for absolute coronary flow and microvascular resistance measurements. *Catheter Cardiovasc Interv.* 2022;100:199-206.

11. Candreva A, Gallinoro E, van't Veer M, Sonck J, Collet C, Di Gioia G, Kodeboina M, Mizukami T, Nagumo S, Keulards D, Fournier S, Pijls NHJ, De Bruyne B. Basics of Coronary Thermodilution. *JACC Cardiovasc Interv.* 2021;14:595-605.

12. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *EuroIntervention.* 2022;17:e1126-96.

13. Writing Committee Members; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2021;77:e25-197.

14. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015;28:1-39.e14.

15. Negishi K, Negishi T, Kurosawa K, Hristova K, Popescu BA, Vinereanu D, Yuda S, Marwick TH. Practical guidance in echocardiographic assessment of global longitudinal strain. *JACC Cardiovasc Imaging.* 2015;8:489-92.

16. Voigt JU, Mălăescu GG, Haugaa K, Badano L. How to do LA strain. *Eur Heart J Cardiovasc Imaging.* 2020;21:715-7.

17. Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, D'Hooge J, Donal E, Fraser AG, Marwick T, Mertens L, Popescu BA, Sengupta PP, Lancellotti P, Thomas JD, Voigt JU; Industry representatives; Reviewers: This document was reviewed by members of the 2016–2018 EACVI Scientific Documents Committee. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging.* 2018;19:591-600.

18. Pighi M, Fezzi S, Pesarini G, Venturi G, Giovannini D, Castaldi G, Lunardi M, Ferrero V, Scarsini R, Ribichini F. Extravalvular Cardiac Damage and Renal Function Following Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. *Can J Cardiol.* 2021;37:904-12.

19. De Vos A, Jansen TPJ, van 't Veer M, Dimitriu-Leen A, Konst RE, Elias-Smale S, Paradies V, Rodwell L, van den Oord S, Smits P, van Royen N, Pijls N, Damman P. Microvascular Resistance Reserve to Assess Microvascular Dysfunction in ANOCA Patients. *JACC Cardiovasc Interv.* 2023;16:470-81.

20. Rajappan K, Rimoldi OE, Dutka DP, Ariff B, Pennell DJ, Sheridan DJ, Camici PG. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. *Circulation.* 2002;105:470-6.

21. Ahmad Y, Götberg M, Cook C, Howard JP, Malik I, Mikhail G, Frame A, Petraco R, Rajkumar C, Demir O, Iglesias JF, Bhindi R, Koul S, Hadjiloizou N, Gerber R, Ramrakha P, Ruparelia N, Sutaria N, Kanaganayagam G, Ariff B, Fertleman M, Anderson J, Chukwuemeka A, Francis D, Mayet J, Serruys P, Davies J, Sen S. Coronary Hemodynamics in Patients With Severe Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement: Implications for Clinical Indices of Coronary Stenosis Severity. *JACC Cardiovasc Interv.* 2018;11:2019-31.

22. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation.* 2003;107:984-91.

23. Rosa VEE, Ribeiro HB, Sampaio RO, Morais TC, Rosa MEE, Pires LJT, Vieira MLC, Mathias W Jr, Rochitte CE, de Santis ASAL, Fernandes JRC, Accorsi TAD, Pomerantzeff PMA, Rodés-Cabau J, Pibarot P, Tarasoutchi F. Myocardial Fibrosis in Classical Low-Flow, Low-Gradient Aortic Stenosis. *Circ Cardiovasc Imaging.* 2019;12:e008353.

24. Herrmann S, Störk S, Niemann M, Lange V, Strotmann JM, Frantz S, Beer M, Gattenlöhner S, Voelker W, Ertl G, Weidemann F. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. *J Am Coll Cardiol.* 2011;58:402-12.

# Supplementary data

**Supplementary Appendix 1.** Exclusion criteria across the three enrolling centres.
**Supplementary Appendix 2.** Coronary microcirculatory assessment.
**Supplementary Appendix 3.** Evaluation of extravalvular cardiac damage.
**Supplementary Table 1.** Association between MRR and EVCD at different MRR cutoffs.
**Supplementary Table 2.** Predictors of the lower tertile of MRR at univariable and multivariable logistic regression analysis.

**Supplementary data**

**Supplementary Appendix 1. Exclusion criteria across the three enrolling centres.**

*Exclusion criteria Verona University Hospital*

Exclusion criteria were: (1) unwilling or unable to provide written informed consent; (2) previous coronary artery bypass graft; (3) significant angiographic stenosis (> 50%) on the left anterior descending; (4) previous anterior myocardial infarction; (5) severe chronic kidney disease; (6) concomitant severe aortic or mitral regurgitation; (7) history of infiltrative myocardial disease.

*Exclusion criteria Aalst OLV Cardiovascular Center*

Inclusion criteria were: 1) presence of normal-flow high gradient severe aortic stenosis in accordance with current ESC Guidelines; 2) absence of significant epicardial stenosis in the left anterior descending artery (LAD) (defined as diameter stenosis [DS] > 50% by visual estimation). Exclusion criteria were: 1) previous myocardial infarction (MI) or coronary artery bypass graft (CABG) in the LAD territory; 2) Valve-in-valve procedure; 3) left ventricular ejection fraction < 50%; 4) low-flow low-gradient or paradoxical low-flow low gradient aortic stenosis; 5) left bundle branch-block or right ventricular pacing.

*Exclusion criteria Milan San Raffaele Hospital*

Exclusion criteria were: 1. Age <18 years. 2. Inability to express informed consent to take part in the present study. 3. Pregnancy or lactation. 4. Pre-existing known disease determining a prognosis quod vitam shorter than the follow up of the present study. 5. Significant chronic kidney disease (estimated glomerular filtration rate <30 ml/min). 6. Known significant epicardial coronary artery stenosis. 7. Known contraindication to adenosine administration: a. Known allergic reactions. b. Second or third degree atrioventricular block before the procedure (in absence of a functional permanent pacemaker). c. Long QT syndrome. d. Unstable angina. e. Severe hypotension. f. Acutely decompensated heart failure. g. Chronic obstructive pulmonary disease with bronchospasm. h. Concomitant use of dypiridamole.

**Supplementary Appendix 2. Coronary microcirculatory assessment.**

*Intracoronary continuous thermodilution*

Absolute coronary flow (Q, mL/min) was derived with continuous intracoronary thermodilution of saline at room temperature in the LAD using the following validated formula:

$$1. \quad Q = 1.08 \frac{Ti}{T} Qi$$

Resting absolute coronary flow ($Q_{rest}$) was measured with saline infusion at 10 mL/min, while hyperemic flow ($Q_{hyp}$) was measured with saline infusion at 20 mL/min. Absolute resistance (Wood units [WU]) at rest ($R_{\mu\text{-rest}}$) and during hyperemia ($R_{\mu\text{-hyp}}$) were calculated as the ratio between the distal coronary pressure during each infusion (Pd) and $Q_{rest}$ or $Q_{hyp}$ respectively. Using continuous thermodilution, CFR is calculated as the ratio between $Q_{hyp}$ and $Q_{rest.}$

*Intracoronary bolus thermodilution*

Coronary flow velocity was estimated using bolus thermodilution to derive mean transit time and analyzed with the Coroflow software (Coroventis, Uppsala, Sweden). Maximal hyperemia was induced with intravenous adenosine infusion (140 mcg/kg/min). Fractional flow reserve was measured as per standard practice as the ratio between distal pressure and aortic pressure during steady-state hyperemia.

IMR was defined as previously described as:

$$IMR = Pd \text{ hyp} \times \text{mean transit time (hyperemia)}$$

CFR was calculated using the equation:

$$CFR = \text{mean transit time (resting)} / \text{mean transit time (hyperemia)}$$

Resistive reserve ratio (RRR) was calculated using the following equation:

$$RRR = \frac{Pd \ (rest) \cdot mean \ transit \ time \ (rest)}{Pd \ (hyp) \cdot mean \ transit \ time \ (hyp)}$$

**Supplementary Appendix 3. Evaluation of extravalvular cardiac damage.**

According to the previously published and well-validated Genereux staging, extravalvular cardiac damage was categorized into 5 stages (patients were classified in one given stage [the worst one] if with at least one of the criteria of that stage):

- stage 0: no cardiac damage;

- stage 1: left ventricular damage; left ventricular mass index > 115 g/m2 (male), > 95 g/m2 (female), E/E' > 14, LVEF <50%;

- stage 2: left atrial or mitral damage; left atrial volume index > 34 ml/m2, moderate to severe mitral regurgitation, atrial fibrillation;

- stage 3: pulmonary vasculature or tricuspid damage: sPAP $\geq$ 60 mmHg, moderate to severe tricuspidalic regurgitation;

- stage 4; right ventricular damage; moderate to severe right ventricular dysfunction;

In this study extravalvular cardiac damage was dichotomized in Genereux stages 0-2 (isolated left heart dysfunction) and Genereux stages 3-4 (right heart involvement, advanced extravalvular cardiac damage).

**Supplementary Table 1. Association between MRR and EVCD at different MRR cutoffs.**

|  | MRR < 2.1 | MRR ≥ 2.1 | p value |
|---|---|---|---|
| Advanced EVCD (Genereux stages 3-4) | 17 (37.0%) | 14 (15.9%) | 0.009 |
|  | MRR < 3.0 | MRR ≥ 3.0 | p value |
| Advanced EVCD (Genereux stages 3-4) | 22 (25.6%) | 9 (18.8%) | 0.402 |
| EVCD: extravalvular cardiac damage; MRR: microvascular resistance reserve; | | | |

**Supplementary Table 2. Predictors of the lower tertile of MRR at univariable and multivariable logistic regression analysis.**

| | | |
|---|---|---|
| **Univariable** | | |
| | OR (95% CI) | p value |
| Female gender | **2.523 (1.136-5.604)** | **0.023** |
| Age (years) | 1.057 (0.977-1.144) | 0.168 |
| BMI (kg/m2) | 0.964 (0.888-1.045) | 0.372 |
| Hypertension | 0.747 (0.296-.1887) | 0.537 |
| Dyslipidemia | 1.074 (0.480-2.406) | 0.862 |
| Diabetes | 1.323 (0.624-2.802) | 0.465 |
| Smoker (current or former) | 0.916 (0.362-2.319) | 0.853 |
| eGFR CG < 65 ml/min | **3.582 (1.671-7.677)** | **0.001** |
| Atrial fibrillation | **2.630 (1.194-5.791)** | **0.016** |
| Peripheral vascular disease | 1.233 (0.493-3.087) | 0.654 |
| Previous PCI | 0.367 (0.077-1.754) | 0.209 |
| Mean gradient (mmHg) | 0.980 (0.957-1.005) | 0.108 |
| LVEF (%) | 0.980 (0.949-1.013) | 0.235 |
| LV mass index (g/m2) | 1.003 (0.990-.1016) | 0.675 |
| MR more than mild | 0.871 (0.397-1.909) | 0.729 |
| E/E' | 1.012 (0.949-1.079) | 0.713 |
| LAV index (ml/m2) | 1.001 (0.975-1.027) | 0.941 |
| Advanced EVCD (Genereux stages 3-4) | **3.253 (1.418-7.459)** | **0.005** |
| Low-flow phenotype (SVi < 30 ml/m2) | **2.865 (1.082-7.582)** | **0.034** |
| **Multivariable** | | |
| | aOR (95% CI) | p value |
| Female gender | **3.651 (1.365-9.766)** | **0.010** |
| eGFR CG < 65 ml/min | **4.455 (1.857-10.686)** | **0.001** |
| Advanced EVCD (Genereux stages 3-4) | **3.077 (1.220-7.761)** | **0.017** |
| Low-flow phenotype (SVi < 30 ml/m2) | **3.365 (1.082-10.468)** | **0.036** |

aOR: adjusted odds ratio; BMI: body mass index; eGFR: estimated glomerular filtration rate - Cockcroft Gault; EVCD: extravalvular cardiac damage; OR=odds ratio; LAV: left atrial volume; LV: left ventricular; LVEF=left ventricular ejection fraction; MR: mitral regurgitation; MRR: microvascular resistance reserve; PCI=percutaneous coronary intervention;

**Supplementary Table 3. Predictors of early recovery of MRR after TAVI at univariable and multivariable logistic regression analysis.**

| Univariable | | |
|---|---|---|
| | OR (95% CI) | p value |
| Female gender | **0.228 (0.087-0.600)** | **0.003** |
| Age (years) | **1.160 (1.051-1.279)** | **0.003** |
| BMI (kg/m2) | 0.948 (0.864-1.039) | 0.255 |
| Hypertension | 0.807 (0.299-2.180) | 0.672 |
| Dyslipidemia | 1.024 (0.434-2.418) | 0.956 |
| Diabetes | 1.361 (0.602-3.073) | 0.459 |
| Smoker (current or former) | 1.065 (0.400-2.835) | 0.900 |
| eGFR CG < 65 ml/min | 2.201 (0.994-4.872) | 0.052 |
| Atrial fibrillation | 0.481 (0.180-1.289) | 0.146 |
| Peripheral vascular disease | 0.514 (0.161-1.639) | 0.261 |
| Previous PCI | 0.210 (0.026-1.693) | 0.143 |
| Mean gradient (mmHg) | 1.019 (0.994-1.045) | 0.140 |
| LVEF (%) | **1.061 (1.010-1.116)** | **0.019** |
| LV mass index (g/m2) | 0.991 (0.976-1.007) | 0.275 |
| MR more than mild | 1.125 (0.494-2.564) | 0.779 |
| E/E' | 0.949 (0.881-1.022) | 0.168 |
| LAV index (ml/m2) | 0.992 (0.963-1.021) | 0.570 |
| Advanced EVCD (Genereux stages 3-4) | 1.809 (0.753-4.346) | 0.185 |
| Low-flow phenotype (SVi < 30 ml/m2) | 0.539 (0.167-1.742) | 0.302 |
| Left ventricular end diastolic pressure pre TAVI | 1.018 (0.969-1.070) | 0.484 |
| Multivariable | | |
| | aOR (95% CI) | p value |
| Female gender | **0.311 (0.108-0.895)** | **0.030** |
| Age (years) | **1.155 (1.040-1.282)** | **0.007** |
| eGFR CG < 65 ml/min | 2.419 (0.990-5.909) | 0.053 |
| LVEF (%) | **1.066 (1.044-1.133)** | **0.036** |

aOR: adjusted odds ratio; BMI: body mass index; eGFR: estimated glomerular filtration rate - Cockcroft Gault; EVCD: extravalvular cardiac damage; OR=odds ratio; LAV: left atrial volume; LV: left ventricular; LVEF=left ventricular ejection fraction; MR: mitral regurgitation; MRR: microvascular resistance reserve; PCI=percutaneous coronary intervention; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 1.** Study flowchart.

AS: aortic stenosis; CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 2.** Coronary physiology data according to the Généreux staging.

Overall, across the Genereux stages of extravalvular cardiac damage MRR and CFR are lower in advanced stages of extravalvular cardiac damage.

CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 3.** Correlation between MRR, stroke volume index and PALS.

MRR was significantly correlated with stroke volume index and PALS.

MRR: microvascular resistance reserve; PALS: peak atrial longitudinal strain; SVi: stroke volume index; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 4.** Variations in coronary physiology immediately after TAVI.

Overall MRR (upper left panel) showed a trend toward improvement immediately after TAVI while CFR, RRR and FFR did not change significantly.

CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 5.** Variations in coronary physiology immediately after TAVI in patients with low MRR pre-TAVI.

In patients with a low pre-TAVI MRR CFR, RRR and MRR increased significantly immediately after TAVI (upper right, lower left and upper left panels).

CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation;

**Supplementary Figure 6.** Acute variations in coronary physiology immediately after TAVI in patients with advanced EVCD.

In patients with a pre-TAVI advanced EVCD MRR (upper left panel) significantly increased immediately after TAVI while RRR showed a trend toward increase (lower left panel).

CFR: coronary flow reserve; FFR: fractional flow reserve; MRR: microvascular resistance reserve; RRR: resistive reserve ratio; TAVI: transcatheter aortic valve implantation;